esmo daily reporter talk: the role of cdk4/6 inhibitors in the early stage of #breastcancer.
Published 4 years ago • 1.2K plays • Length 21:47Download video MP4
Download video MP3
Similar videos
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
21:35
educational sessions: "cdk4/6 for er "
-
6:15
breast cancer at esmo 2020: cdk4/6 inhibitors and checkpoint inhibitors
-
2:02
her2-low breast cancer: the esmo expert consensus statements
-
9:08
verzenio (abemaciclib) for breast cancer: who gets it? what are the side effects?
-
7:18
kisqali (ribociclib): side effects and what to expect
-
12:51
how to manage side effects of common aromatase inhibitors for breast cancer
-
23:44
park and graff explore the evolving role of cdk4/6 inhibitors in metastatic breast cancer
-
5:45
#esmo21 expert video report on targeting in her2-positive metastatic breast and lung cancers
-
12:35
episode 1: role of quantitative radionuclide imaging in cardiac amyloidosis
-
1:03
key lectures from esmo breast cancer 2022
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:54
cell cycle inhibitors - cdk4/6 inhibitors
-
46:47
breast cancer insights from esmo 2024
-
1:31
esmo oncologypro - intro by prof. a. matikas
-
2:01
#esmobreast24: international breast cancer experts explain why you should submit your research
-
1:46
#esmobreast24: reasons to attend this top, international congress for the breast cancer community
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
7:13
the biological rationale for cdk4/6 inhibitors